The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

A new study found that Ozempic's main ingredient may treat people with type 1 diabetes, control blood sugar, and lose weight.

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Ozempic is ubiquitous, but it wasn't always this way. The new trend was explored on the latest "Well with Arielle Lorre." ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

Diabetes drug semaglutide linked to reduced risk of dementia in type 2 diabetes patients Effects strongest in women and older ...